Gene Solutions Showcases Advances in MRD at Singapore Oncology Meeting

At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), held on October 15, 2025, Gene Solutions unveiled significant advancements in Molecular Residual Disease (MRD) and multi-omics technologies. This presentation highlighted a shift in cancer care from reactive to proactive approaches, emphasizing the potential of these innovations to enhance precision oncology across the Asia-Pacific region.

Exploring the Potential of MRD and Multi-Omics

The symposium, titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,” brought together prominent oncologists and molecular biology experts. They examined how circulating tumor DNA (ctDNA) MRD and multi-omics technologies can support clinicians and researchers in their fight against cancer.

MRD assays assess ctDNA in the bloodstream, allowing for monitoring at the molecular level. Experts discussed the implications of this technology, which may lead to improved detection of cancer recurrence and more tailored treatment strategies.

Gene Solutions differentiates itself with an innovative platform that integrates DNA, RNA, and AI-enhanced multi-omics signals. This comprehensive approach aims to enhance ctDNA sensitivity, identify complex gene fusions, and determine primary tumor locations. These advancements provide deeper insights, enabling more informed and personalized treatment decisions.

Scientific Validation and Collaborative Efforts

Recent studies, including findings published in JCO Oncology Advances and npj Breast Cancer, underscore the promise of ctDNA-based MRD testing. These studies indicate its potential to predict early recurrence of cancer and contribute to cost-effective monitoring strategies in real-world settings.

With a CAP-accredited laboratory in Singapore and a global operational network, Gene Solutions is committed to fostering scientific collaboration. This initiative aims to advance genomic research and precision oncology throughout the Asia-Pacific region.

Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, emphasized the importance of collaboration, stating, “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively. We invite oncologists, researchers, and healthcare partners across Asia-Pacific to collaborate in advancing these technologies.”

Gene Solutions is a multinational biotechnology company that leads in genetic testing and research innovation across the Asia-Pacific region. Utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence, the company provides an extensive range of advanced solutions. With over two million genetic tests conducted, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and contributions to advancing precision medicine through clinical studies, technology development, and regional partnerships.

For further insights into the symposium and its highlights, visit Gene Solutions’ official website.